ARTICLE | Clinical News

Melinta reports Phase I data for acne candidate radezolid

October 13, 2017 12:35 AM UTC

Melinta Therapeutics Inc. (New Haven, Conn.) reported data from a Phase I trial in 10 patients with mild to moderate acne vulgaris showing that twice-daily topical radezolid (RX-1741) for 4 weeks was well tolerated with minimal systemic absorption...

BCIQ Company Profiles

Melinta Therapeutics LLC

BCIQ Target Profiles

Ribosomal 50S subunit